Mehrdad Mazdak1, Rieke Ringlstetter1,2, Pouriya Faraj Tabrizi1, Meryem Akkoyun1, Mathias Wolters1, Jessica Schmitz3, Jan Hinrich Bräsen3, Inga Peters1, Markus Antonius Kuczyk1, Hossein Tezval4. 1. Department of Urology and Urological Oncology, Hanover Medical School (MHH), Carl-Neuberg-Straße 1, 30625, Hanover, Germany. 2. Department of Information and Communication, Faculty III, University of Applied Sciences and Arts Hanover, 30539, Hanover, Germany. 3. Department of Pathology, Hanover Medical School (MHH), 30625, Hanover, Germany. 4. Department of Urology and Urological Oncology, Hanover Medical School (MHH), Carl-Neuberg-Straße 1, 30625, Hanover, Germany. Tezval.Hossein@mh-hannover.de.
Abstract
INTRODUCTION: Renal cell carcinoma (RCC), an immunogenic tumor, is the most common form of kidney cancer worldwide. Immune checkpoint inhibitors (ICIs) play an important role in the treatment of metastatic RCC. Programmed death-ligand (PD-L1) has already been proposed as a possible prognosticator for ICIs effectiveness. To elucidate the feasible role of ICIs in neoadjuvant settings, we have assessed the most common PD-L1 expression modalities [tumor proportion score (TPS), combined positivity score (CPS) and inflammatory cell (IC) score] in primary tumors (PTs) and venous tumor thrombi (VTT) in first diagnosed, previously untreated RCC patients with accompanying VTT. METHODS: Between January 1999 and December 2016, 71 patients with a first diagnosed, untreated, locally advanced RCC (aRCC) (≥ pT3a) underwent surgery in Hanover Medical School (MHH). PD-L1 expression was examined separately in PTs and VTT using the CPS, IC score and TPS. We also considered the age at the time of the initial surgery and gender as probable influencing factors. By using a cutoff value of 1 (1%), PD-L1 expression levels in PTs and VTT were assessed to enable the determination of any frequency differences. RESULTS: Positive scores for PTs were shown by 54 (CPS), 53 (IC score) and 34 (TPS) patients, whereas in VTT, positive scores were evaluated for a total of 50 (CPS), 47 (IC-score) and 36 (TPS) patients. No statistically significant differences were obtained between the PD-L1 expression immunoscores for PTs and VTT. The covariates age at the time of the initial surgery and gender could not be statistically proven to influence the differences in PD-L1 expression between the VTT and PTs. CONCLUSION: To the best of our knowledge, this research is the largest study to investigate PD-L1 expression in PTs and VTT in 71 cases. It could have relevance for the future development of neoadjuvant immunotherapy options, particularly in aRCC with VTT.
INTRODUCTION:Renal cell carcinoma (RCC), an immunogenic tumor, is the most common form of kidney cancer worldwide. Immune checkpoint inhibitors (ICIs) play an important role in the treatment of metastatic RCC. Programmed death-ligand (PD-L1) has already been proposed as a possible prognosticator for ICIs effectiveness. To elucidate the feasible role of ICIs in neoadjuvant settings, we have assessed the most common PD-L1 expression modalities [tumor proportion score (TPS), combined positivity score (CPS) and inflammatory cell (IC) score] in primary tumors (PTs) and venous tumor thrombi (VTT) in first diagnosed, previously untreated RCCpatients with accompanying VTT. METHODS: Between January 1999 and December 2016, 71 patients with a first diagnosed, untreated, locally advanced RCC (aRCC) (≥ pT3a) underwent surgery in Hanover Medical School (MHH). PD-L1 expression was examined separately in PTs and VTT using the CPS, IC score and TPS. We also considered the age at the time of the initial surgery and gender as probable influencing factors. By using a cutoff value of 1 (1%), PD-L1 expression levels in PTs and VTT were assessed to enable the determination of any frequency differences. RESULTS: Positive scores for PTs were shown by 54 (CPS), 53 (IC score) and 34 (TPS) patients, whereas in VTT, positive scores were evaluated for a total of 50 (CPS), 47 (IC-score) and 36 (TPS) patients. No statistically significant differences were obtained between the PD-L1 expression immunoscores for PTs and VTT. The covariates age at the time of the initial surgery and gender could not be statistically proven to influence the differences in PD-L1 expression between the VTT and PTs. CONCLUSION: To the best of our knowledge, this research is the largest study to investigate PD-L1 expression in PTs and VTT in 71 cases. It could have relevance for the future development of neoadjuvant immunotherapy options, particularly in aRCC with VTT.
Authors: Marcella Callea; Laurence Albiges; Mamta Gupta; Su-Chun Cheng; Elizabeth M Genega; André P Fay; Jiaxi Song; Ingrid Carvo; Rupal S Bhatt; Michael B Atkins; F Stephen Hodi; Toni K Choueiri; David F McDermott; Gordon J Freeman; Sabina Signoretti Journal: Cancer Immunol Res Date: 2015-05-26 Impact factor: 11.151
Authors: Gorka Larrinaga; Jon Danel Solano-Iturri; Peio Errarte; Miguel Unda; Ana Loizaga-Iriarte; Amparo Pérez-Fernández; Enrique Echevarría; Aintzane Asumendi; Claudia Manini; Javier C Angulo; José I López Journal: Cancers (Basel) Date: 2021-02-07 Impact factor: 6.639
Authors: Alexander Laird; Fiach C O'Mahony; Jyoti Nanda; Antony C P Riddick; Marie O'Donnell; David J Harrison; Grant D Stewart Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240